Lengthened WHI Follow-up

Postmenopausal Estrogen Therapy

Andrew M. Kaunitz, MD


Journal Watch 

In This Article

Abstract and Introduction


Women's Health Initiative follow-up of postintervention phase showed estrogen had no substantial adverse effects on most health outcomes; reduction in relative risk for breast cancer persisted.


In the Women's Health Initiative (WHI) Estrogen-Alone Trial, 11,000 postmenopausal women with hysterectomies (age range at baseline, 50–79) received conjugated equine estrogen or placebo for a median of 5.9 years; the trial was stopped at mean follow-up of 7.1 years when initial findings showed excess risk for stroke in the estrogen group. Subsequent analysis showed that, in younger WHI participants (age range at baseline, 50–59), estrogen use was associated with lower risk for coronary heart disease (CHD) and overall mortality during the intervention period. Now, investigators have assessed postintervention health outcomes in 7645 WHI participants.

Overall, at a mean 10.7 years after baseline, estrogen use was not associated with excess risk for stroke or other adverse outcomes (CHD, deep venous thrombosis, hip fracture, colorectal cancer, and mortality during follow-up). As had been noted in previous WHI analyses of the intervention phase, risk for invasive breast cancer was lower in the estrogen group than in the placebo group (hazard ratio, 0.77; 95% confidence interval, 0.62–0.95); moreover, among younger women, estrogen use was associated with lower risk for CHD (HR, 0.59; 95% CI, 0.38–0.90) and marginally lower risk for mortality during follow-up (HR, 0.73; 95% CI, 0.53–1.00).


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.